Based on these studies, patients with human epidermal growth factor receptor-2 (HER-2)-negative advanced gastric cancers with high programmed death ligand-1 (PD-L1) expression should be treated with platinum-fluoropyrimidine doublet combined with PD-1 inhibitor. The gene discussed is CD274; the disease is gastric cancer.